Drug Profile
Romiplostim - Amgen
Alternative Names: AMG-531; Nplate; RomiplateLatest Information Update: 01 Dec 2023
Price :
$50
*
At a glance
- Originator Kirin-Amgen
- Developer Amgen; Kirin-Amgen
- Class Antianaemics; Carrier proteins; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura
- Registered Acute radiation syndrome
- Phase III Thrombocytopenia
- Phase I/II Myelodysplastic syndromes
Most Recent Events
- 13 Nov 2023 Memorial Sloan Kettering Cancer Center in collaboration with Amgen completes phase-II clinical trial in Thrombocytopenia in US (SC) (NCT02052882)
- 30 Sep 2023 Preregistration for Aplastic anaemia (Treatment-experienced) in Hong Kong (SC) in September 2023(Kyowa Kirin pipeline, February 2024)
- 29 Sep 2023 Amgen withdraws a phase II trial in Aplastic anaemia (Treatment-experienced) (SC), due to operational reasons (NCT05323617)